nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

22.03.2017 | Original Article

Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline

verfasst von: Nare Torosyan, Kelsey Mason, Magnus Dahlbom, Daniel H. S. Silverman, the Alzheimer’sDisease Neuroimaging Initiative

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI).

Methods

Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer’s Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer’s disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores. PET images were analyzed using clinically routine brain quantification software. A dementia prognosis index (DPI), derived from a ratio of uptake values in regions of interest known to be hypometabolic in Alzheimer’s disease to regions known to be stable, was generated for each baseline FDG-PET scan. The DPI was correlated with change in scores on the neuropsychological examinations to examine the predictive value of baseline FDG-PET.

Results

DPI powerfully predicted rate of functional decline among MCI patients (t = 5.75, p < 1.0E-8) and pooled N + MCI patient groups (t = 7.02, p < 1.0E-11). Rate of cognitive decline on MMSE was also predicted by the DPI among MCI (t = 6.96, p < 1.0E-10) and pooled N + MCI (t = 8.78, p < 5.0E-16). Rate of cognitive decline on ADAS-cog was powerfully predicted by the DPI alone among N (p < 0.001), MCI (t = 6.46, p < 1.0E-9) and for pooled N + MCI (t = 8.85, p = 1.1E-16).

Conclusions

These findings suggest that an index, derivable from automated regional analysis of brain PET scans, can be used to help predict rates of functional and cognitive deterioration in the years following baseline PET.

Association As. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12:459–509.CrossRef

Eshkoor SA, Hamid TA, Mun CY, Ng CK. Mild cognitive impairment and its management in older people. Clin Interv Aging. 2015;10:687–93. doi:10.2147/CIA.S73922.CrossRefPubMedPubMedCentral

Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking; 2006.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement: J Alzheimers Assoc. 2011;7:280–92. doi:10.1016/j.jalz.2011.03.003.CrossRef

Ishii K. PET approaches for diagnosis of dementia. Am J Neuroradiol. 2014;35:2030–8. doi:10.3174/ajnr.A3695.CrossRefPubMed

Silverman DS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–7. doi:10.1001/jama.286.17.2120.CrossRefPubMed

Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42:85–94. doi:10.1002/ana.410420114.CrossRefPubMed

Pfeffer RI, Kurosaki TT, Harrah Jr CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–9.CrossRefPubMed

Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–64.CrossRefPubMed

10.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. doi:10.1016/0022-3956(75)90026-6.CrossRefPubMed

11.

Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1994;2:189–210. doi:10.1002/hbm.460020402.CrossRef

12.

Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RSJ. Spatial registration and normalization of images. Hum Brain Mapp. 1995;3:165–89. doi:10.1002/hbm.460030303.CrossRef

13.

Ashburner J, Barnes G, Chen C. SPM8 manual Wellcome Trust Centre for Neuroimaging 1-475.

14.

Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Thieme Medical Publishers

15.

Lindbergh CA, Dishman RK, Miller LS. Functional disability in mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev. 2016;26:129–59. doi:10.1007/s11065-016-9321-5.CrossRefPubMed

16.

Roy K, Pepin LC, Philiossaint M, Lorius N, Becker JA, Locascio JJ, et al. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer’s disease spectrum. J Alzheimers Dis : JAD. 2014;42:291–300. doi:10.3233/JAD-131796.PubMedPubMedCentral

17.

Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med. 2002;16:515–25. doi:10.1007/BF02988628.CrossRefPubMed

18.

Brown RKJ, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brain PET in suspected dementia: patterns of altered FDG metabolism. RadioGraphics. 2014;34:684–701. doi:10.1148/rg.343135065.CrossRefPubMed

19.

Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev. 2016;30:73–84. doi:10.1016/j.arr.2016.02.003.CrossRefPubMed

20.

Berti V, Mosconi L, Pupi A. Brain: normal variations and benign findings in FDG PET/CT imaging. PET Clin. 2014;9:129–40. doi:10.1016/j.cpet.2013.10.006.CrossRefPubMed

21.

Pardo JV, Lee JT, Sheikh SA, Surerus-Johnson C, Shah H, Munch KR, et al. Where the brain grows old: decline in anterior cingulate and medial prefrontal function with normal aging. NeuroImage. 2007;35:1231–7. doi:10.1016/j.neuroimage.2006.12.044.CrossRefPubMedPubMedCentral

22.

Kakimoto A, Ito S, Okada H, Nishizawa S, Minoshima S, Ouchi Y. Age-related sex-specific changes in brain metabolism and morphology. J Nucl Med. 2016;57:221–5. doi:10.2967/jnumed.115.166439.CrossRefPubMed

23.

Ewers M, Brendel M, Rizk-Jackson A, Rominger A, Bartenstein P, Schuff N, et al. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. NeuroImage : Clinical. 2014;4:45–52. doi:10.1016/j.nicl.2013.10.018.CrossRef

24.

Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M. Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013;8:e74062. doi:10.1371/journal.pone.0074062.CrossRefPubMedPubMedCentral

25.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–13. doi:10.1007/s00259-003-1194-1.CrossRefPubMed

26.

Cerami C, Della Rosa PA, Magnani G, Santangelo R, Marcone A, Cappa SF, et al. Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia. NeuroImage: Clinical. 2015;7:187–94. doi:10.1016/j.nicl.2014.12.004.CrossRef

27.

Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012;66:185–98. doi:10.1111/j.1742-1241.2011.02845.x.CrossRefPubMed

28.

Chen K, Ayutyanont N, Langbaum JBS, Fleisher AS, Reschke C, Lee W, et al. Characterizing Alzheimer’s disease using a hypometabolic convergence index. NeuroImage. 2011;56:52–60. doi:10.1016/j.neuroimage.2011.01.049.CrossRefPubMedPubMedCentral

29.

Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18. doi:10.1016/j.neurobiolaging.2009.07.002.CrossRefPubMed

30.

Mallik A, Drzezga A, Minoshima S. Clinical amyloid imaging. Semin Nucl Med. 2017;47:31–43. doi:10.1053/j.semnuclmed.2016.09.005.CrossRefPubMed

31.

Okamura N, Harada R, Furukawa K, Furumoto S, Tago T, Yanai K, et al. Advances in the development of tau PET radiotracers and their clinical applications. Ageing Res Rev. 2016;30:107–13. doi:10.1016/j.arr.2015.12.010.CrossRefPubMed

32.

Marzanski M. On telling the truth to patients with dementia. West J Med. 2000;173:318–23.CrossRefPubMedPubMedCentral

33.

Elson P. Do older adults presenting with memory complaints wish to be told if later diagnosed with Alzheimer’s disease? Int J Geriatr Psychiatry. 2006;21:419–25. doi:10.1002/gps.1485.CrossRefPubMed

34.

Alzheimer’s A. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11:332–84.CrossRef

35.

Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92. doi:10.1001/archneur.58.12.1985.CrossRefPubMed

Titel: Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline
verfasst von: Nare Torosyan
Kelsey Mason
Magnus Dahlbom
Daniel H. S. Silverman
the Alzheimer’sDisease Neuroimaging Initiative
Publikationsdatum: 22.03.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3634-3

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis

Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer

Comparison of CT and PET/CT for biopsy guidance in oncological patients

Valentina Ambrosini and Stefano Fanti (eds): Clinicians’ Guides to Radionuclide Hybrid Imaging: PET/CT in Neuroendocrine Tumors

Hypercalcemia revealing diffuse granulomatous myositis

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT